Pentoxifylline reduces the inflammatory process in diabetic rats: Relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase

Journal of Inflammation (United Kingdom)

Volumn 12, Issue 1, 2015, Pages

  Garcia, Francisca Adilfa De Oliveira ^a   Rebouças, Jéssica Farias ^a   Balbino, Teresa Queiroz ^a   Da Silva, Teresinha Gonçalves ^b   De Carvalho Júnior, Carlson Hélder Reis ^b   Cerqueira, Gilberto Santos ^c   Brito, Gerly Anne De Castro ^c   Viana, Glauce Socorro De Barros ^a,c  

^a Laboratory of Pharmacology and Physiology   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Cytokines; Diabetes mellitus; Inflammation; Oxidative stress; Pentoxifylline

Indexed keywords

ALLOXAN; CARRAGEENAN; GLIBENCLAMIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PAW EDEMA; PROTEIN EXPRESSION; RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84928537610     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/s12950-015-0080-5     Document Type: Article

References (70)

1. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant. 2005;20:2601-4.
2. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol. 1993;143:1649-56.
3. Ortiz A, Gonzalez-Cuadrado S, Bustos C, Alonso J, Homez-Guerrero C, Lopez-Armada MJ, et al. Tumor necrosis factor and glomerular damage. J Nephrol. 1995;8:27-34.
4. Schmidt AM, Yan SD, Wautier JL, Stern DM. Activation of receptor for advanced glycation end products - a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-97.
5. Romano M, Pomilio M, Vigneri S, Falco A, Chiesa PL, Chiarelli F, et al. Endothelial perturbation in children and adolescents with type 1diabetes: association with markers of the inflammatory reaction. Diabetes Care. 2001;24:1674-8.
6. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, et al. Elevated C-reactive protein associates with early-stage carotida therosclerosis in young subjects with type 1 diabetes. Diabetes Care. 2002;25:1432-8.
7. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergman MM, Ristow MM, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812-7.
8. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527-34.
9. Chen TL, Xu EL, Lu HJ, Xu H, Wang SF, Zhao HJ, et al. The influence of diabetes enhanced inflammation on cell apoptosis and periodontitis. Adv Biosci Biotechnol. 2012;3:712-9.
10. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792-800.
11. Bulló M, Garcia-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis fator and leptin expression. Obes Res. 2003;11:525-31.
12. Sattar N, Perry CG, Petrie JR. Type 2 diabetes as an inflammatory disorder. Br J Diabetes Vasc Dis. 2003;3:36-41.
13. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
14. Sethi JK, Hotamisligil GS. The role of TNF-alpha in adipocyte metabolism. Semin Cell Dev Biol. 1999;10:19-29.
15. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Investig. 1995;95:2409-15.
16. Saghizadeh M. The expression of TNF-alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97:1111-6.
17. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610-4.
18. Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients, with chronic kidney disease-placebo controlled, randomized, cross-over study. Acta Biochim Pol. 2010;57:119-23.
19. Hecht M, Müller M, Lohmann-Mathes ML, Emmendörffer A. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol. 1995;57:242-9.
20. Pollice PF, Rosier RN, Looney RJ, Puzas JE, Schwarz EM, O'Keefe RJ. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am. 2001;83:1057-61.
21. Luna T, Santos SB, Nascimento M, Porto MAF, Muniz AL, Carvalho EM, et al. Effect of TNF-alpha production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Braz J Med Biol Res. 2011;44:1134-40.
22. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15:1877-82.
23. Bilsborough W, O'Driscoll G, Stanton K, Weerasooriya R, Dembo L, Taylor R, et al. Effect of lowering tumour necrosis factor-α on vascular endothelial function in type II diabetes. Clin Sci. 2002;103:163-9.
24. Dorner GT, Zawinka C, Resch H, Wolzt M, Schmetterer L, Garhofer G. Effects of pentoxifylline and alprostadil on ocular hemodynamics in health humans. Invest Olphtalmol Vis Sci. 2007;48:815-9.
25. Flint H, Cotter MA, Cameron NF. Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. Int J Exp Diabetes Res. 2000;1:49-58.
26. Schwartz RW, Logan NM, Johnson PJ, Strodel WE, Fine JG, Kazmers A, et al. Pentoxifylline increases extremity blood flow in diabetixc atherosclerotic patients. Arch Surg. 1989;124:434-7.
27. Sonkin PL, Kelly LW, Sinclair SH, Hatcheli DL. Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes. Arch Olphthalmol. 1993;111:1647-52.
28. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini AS, Zuppi C, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010. doi:10.1900/RDS. 2019.7.15.
29. Guay J, Bateman K, Gordon R, Mancini J, Riendeau D. Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem. 2004;279:24866-72.
30. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008;52:454-63.
31. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis. 1999;33:458-63.
32. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16:2119-26.
33. DiRosa M, Girould JP, Willoughby DA. Studies of mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Pathol. 1971;104:15-29.
34. Siebert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994;91:12013-7.
35. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Ann J Pathol. 1982;107:397-418.
36. Salvemini D, Wang Z-Q, Wyatt PS, Bourdon DM, Marino MH, Manning PT, et al. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol. 1996;118:829-38.
37. Vinegar R, Macklin AM, Truax JF, Selph JL. Histopathological and pharmacological study of carrageenin inflammation in the rat. Pharmacologist. 1971;13:284-90.
38. Boughton-Smith NK, Deakin AM, Follenfant RL, Whittle BJR, Garland LG. Role of oxygen radicals and arachidonic acid metabolites in the reverse passive Arthus reaction and carrageenan paw oedema in the rat. Br J Pharmacol. 1993;110:896-902.
39. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-41.
40. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-12.
41. Francés DE, Ingarano PI, Ronco MT, Carnovale CE. Diabetes, an inflammatory process: oxidative stress and TNF-alpha involved in hepatic complication. J Biomed Sci Eng. 2013;6:645-53.
42. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type e diabetes: from metabolic stress to therapy. Diabetes Care. 2008;34 Suppl 2:S161-4.
43. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis- impact on periodontal pathology. J Dental Res. 2006;85:15-21.
44. Festa A, D'Agostino JR, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, et al. The relation of body fat mass and distribution to marker of chronic inflammation. Int J Obes. 2000;25:1407-15.
45. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med. 2004;21:203-7.
46. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation. 2002;106:2067-72.
47. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192-8.
48. DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol. 2004;24:352-9.
49. Gonzalez Y, Herrera MT, Soldevila G, Garcia-Garcia L, Fabián G, Pérez-Armendariz EM, et al. High glucose concentrations induce TNF-alpha production through the down-regulation of CD33 in primary human monocytes. BMC Immunol. 2012;13:19. http://www.biomedcentral.com/1471-2172/13/19.
50. Loram LC, Fuller A, Fick LG, Cartmell T, Poole S, Mitchell D. Cytokine profiles during carrageenan-induced inflammatory hyperalgesia in rat muscle and hind paw. J Pain. 2007;8:127-36.
51. Seifi B, Kadkhodaee M, Delavari F, Mikaeili S, Shams S, Ostad SN. Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury. Ren Fail. 2012;34:610-5.
52. Barkhordari K, Karimi A, Shafiee A, Soltaninia H, Khatami MR, Abbasi K, et al. Effect of pentoxifylline on preventing acute kidney injury after cardiac surgery by measuring urinary neutrophil gelatinase - associated lipocalin. J Cardiothorac Surg. 2011;6:8. doi:10.1186/1749-8090-6-8.
53. Sun HK, Lee YM, Han KH, Kim HS, Ahn SH, Han SY. Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney. Korean J Intern Med. 2012;27:163-70.
54. Lucchesi AN, Freitas NT, Cassetari LL, Marques SFG, Spadella CT. Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease. Acta Cir Bras. 2013;28:502-8.
55. Ji Q, Zhang L, Jia H, Yang J, Xu J. Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci. 2004;34:427-36.
56. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-70.
57. Fujimoto M, Shimizu N, Kunii K, Martyn JA, Ueki K, Kaneki M. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes. 2005;54:1340-8.
58. Stevens RB, Sutherland DE, Ansite JD, Saxena M, Rossini TJ, Levay-Young BK, et al. Insulin down-regulates the inducible nitric oxide synthase pathway: nitric oxide as cause and effect of diabetes? J Immunol. 1997;159:5329-35.
59. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005;4:5. doi:10.1186/475-2840-4-5.
60. Li D-L, Ma Z-Y, Fu Z-J, Ling M-Y, Yan C-Z, Zhang Y. Glibenclamide decreases ATP-induced intracellular calcium transient elevation via inhibiting reactive oxygen species and mitochondrial activity in macrophages. PLoS ONE. 2014;9:e89083.
61. Schmid D, Svoboda M, Sorgner A, Moraycevic I, Thalhammer T, Chiba P, et al. Glibenclamide reduces pro-inflammatory cytokines in an ex vivo model of human endotoxinaemia under hypoxic conditions. Life Sci. 2011;89:725-34.
62. Cai J, Lu S, Yao Z, Deng Y-P, Zhang L-D, Yu J-W, et al. Glibenclamide attenuates myocardial injury by lipopolysaccharides in streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2014;13:106.
63. Kewcharoenwong C, Rinchai D, Utispan K, Suwannasaen D, Bancroft GJ, Ato M, et al. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. Sci Rep. 2013;3:3363. doi:10.1038/srep03363.
64. Koh CCKW, Maude RR, Schreiber MF, Limmathurotsakul D, Wiersinga WJ, Wuthiekanun V, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis. 2011;52:717-25.
65. Sartoretto JL, Melo GA, Bersani-Amado CA, Oliuveira MA, Santos RA, Passaglia RT, et al. Chlorpropamide treatment restores the reduced carrageenan-induced paw edema and pleural exudate volume in diabetic rats. Inflamm Res. 2008;57:438-43.
66. Thompson MK, Tuma RF, Young WF. The effects of pentoxifylline on spinal cord blood flow after experimental spinal cord injury. J Assoc Acad Minor Phys. 1999;10:23-6.
67. Vakili A, Mojarrad S. Effect of pentoxifylline on brain edema in a rat model of transient focal cerebral ischemia. Physiol Pharmacol. 2009;12:320-7.
68. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30:49-59.
69. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdolhari M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type 2 patients: a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2005;59:302-6.
70. Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vasc Pharmacol. 2007;47:118-24.